Loading...
| A03469 | Pages: NA | Jul 2022 | 5468 Views | | |
| Author(s) : NA | Tables: NA | Charts: NA |
| |
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Disopyramide Phosphate Market
Request Now !Disopyramide phosphate is a class I anti-arrhythmic drug used to treat cardiac arrhythmias. It interferes with the depolarization of the cardiac membrane that results in depressant action on the heart rhythm. The drug is used to treat arrhythmias and prevent paroxysmal supraventricular tachycardia.
The factors that drive the disopyramide phosphate market include increase in the prevalence of arrhythmias and ventricular tachycardia among patients with heart problems, rise in R&D activities to develop advanced products, advanced healthcare set-up, and growth in geriatric population. However, side effects associated with drugs and stringent government regulations towards the approval of disopyramide phosphate drugs restrict the market growth. Increase in clinical trials and development of drugs with better efficacy and lesser side effects biologics are expected to provide a number of opportunities for pharmaceutical industries, thereby fueling the market growth in the near future.
The disopyramide phosphate market is segmented on the basis of brand, patient type, and region. Based on drug brand, it is divided into Norpace, Rythmodan, and others. According to patient type, it is segmented into geriatric, adolescents, children, and infants. Geographically, it has been analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The key players that operate in this market include Sanofi, Merck KGaA, Teva Pharmaceutical Industries Ltd., Santa Cruz Biotechnology, Inc., Mylan N.V., Interpharm Holdings Inc., Watson Laboratories, Inc., Sandoz AG, Pfizer Inc., and Aurolife Pharma LLC.
Key Benefits
CHAPTER 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. MARKET SHARE ANALYSIS, 2016
3.4. PORTER’S FIVE FORCES ANALYSIS
3.5. MARKET DYNAMICS
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities
CHAPTER 4 DISOPYRAMIDE PHOSPHATE MARKET, BY DRUG BRAND
4.1. OVERVIEW
4.1.1. Market size and forecast
4.2. NORPACE
4.2.1. Growth factors and opportunities
4.2.2. Market size and forecast
4.2.3. Market size and forecast
4.3. RYTHMODAN
4.3.1. Growth factors and opportunities
4.3.2. Market size and forecast
4.3.3. Market size and forecast
4.4. OTHERS
4.4.1. Growth factors and opportunities
4.4.2. Market size and forecast
4.4.3. Market size and forecast
CHAPTER 5 DISOPYRAMIDE PHOSPHATE MARKET, BY PATIENT TYPE
5.1. OVERVIEW
5.1.1. Market size and forecast
5.2. GERIATRIC
5.2.1. Market size and forecast
5.3. ADOLESCENTS
5.3.1. Market size and forecast
5.4. CHILDREN
5.4.1. Market size and forecast
5.5. INFANTS
5.5.1. Market size and forecast
CHAPTER 6 DISOPYRAMIDE PHOSPHATE MARKET, BY REGION
6.1. OVERVIEW
6.2. NORTH AMERICA
6.2.1. Key market trends
6.2.2. Key growth factors and opportunities
6.2.3. Market size and forecast
6.2.3.1. U.S. market size and forecast
6.2.3.2. Canada market size and forecast
6.2.3.3. Mexico market size and forecast
6.2.4. North America Disopyramide Phosphate Market by Drug Brand
6.2.5. North America Disopyramide Phosphate Market by Patient Type
6.3. EUROPE
6.3.1. Key market trends
6.3.2. Key growth factors and opportunities
6.3.3. Market size and forecast
6.3.3.1. Germany market size and forecast
6.3.3.2. France market size and forecast
6.3.3.3. UK market size and forecast
6.3.3.4. Italy market size and forecast
6.3.3.5. Spain market size and forecast
6.3.3.6. Rest of Europe market size and forecast
6.3.4. Europe Disopyramide Phosphate Market by Drug Brand
6.3.5. Europe Disopyramide Phosphate Market by Patient Type
6.4. ASIA-PACIFIC
6.4.1. Key market trends
6.4.2. Key growth factors and opportunities
6.4.3. Market size and forecast
6.4.3.1. Japan market size and forecast
6.4.3.2. China market size and forecast
6.4.3.3. Australia market size and forecast
6.4.3.4. India market size and forecast
6.4.3.5. South Korea market size and forecast
6.4.3.6. Rest of Asia-Pacific market size and forecast
6.4.4. Asia-Pacific Disopyramide Phosphate Market by Drug Brand
6.4.5. Asia-Pacific Disopyramide Phosphate Market by Patient Type
6.5. LAMEA
6.5.1. Key market trends
6.5.2. Key growth factors and opportunities
6.5.3. Market size and forecast
6.5.3.1. Brazil market size and forecast
6.5.3.2. Saudi Arabia market size and forecast
6.5.3.3. South Africa market size and forecast
6.5.3.4. Rest of LAMEA market size and forecast
6.5.4. LAMEA Disopyramide Phosphate Market by Drug Brand
6.5.5. LAMEA Disopyramide Phosphate Market by Patient Type
CHAPTER 7 COMPANY PROFILES
7.1. SANOFI
7.1.1. Operating business segments
7.1.2. Business performance
7.1.3. Key strategic moves and developments
7.2. MERCK KGAA
7.2.1. Operating business segments
7.2.2. Business performance
7.2.3. Key strategic moves and developments
7.3. TEVA PHARMACEUTICAL INDUSTRIES LTD.
7.3.1. Operating business segments
7.3.2. Business performance
7.3.3. Key strategic moves and developments
7.4. SANTA CRUZ BIOTECHNOLOGY, INC.
7.4.1. Operating business segments
7.4.2. Business performance
7.4.3. Key strategic moves and developments
7.5. MYLAN N.V.
7.5.1. Operating business segments
7.5.2. Business performance
7.5.3. Key strategic moves and developments
7.6. INTERPHARM HOLDINGS INC.
7.6.1. Operating business segments
7.6.2. Business performance
7.6.3. Key strategic moves and developments
7.7. WATSON LABORATORIES, INC.
7.7.1. Operating business segments
7.7.2. Business performance
7.7.3. Key strategic moves and developments
7.8. SANDOZ AG
7.8.1. Operating business segments
7.8.2. Business performance
7.8.3. Key strategic moves and developments
7.9. PFIZER INC.
7.9.1. Operating business segments
7.9.2. Business performance
7.9.3. Key strategic moves and developments
7.10. AUROLIFE PHARMA LLC
7.10.1. Operating business segments
7.10.2. Business performance
7.10.3. Key strategic moves and developments
Clients can easily download both quantitative as well as
qualitative reports in PDF and excel formats.
Start reading.
This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Buy Now *Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
